Spin-off finds investor

January 10, 2003

Technology commercialisation company BTG will invest in Senexis, a biotechnology company that will develop treatments for ageing-related diseases such as Alzheimer's, Parkinson's and Huntington's.

Senexis, based at the University of Manchester Institute of Science and Technology, has raised £1.4 million from BTG and Catalyst BioMedica Limited to finance its research.

Register to continue

Why register?

  • Registration is free and only takes a moment
  • Once registered, you can read 3 articles a month
  • Sign up for our newsletter
Please Login or Register to read this article.


Featured jobs